A New Turning Point in Biotech Innovation: The 2025 Industry Landscape Shaped by AI-Driven Drug Development
Editor
The biotech industry in 2025 is reaching a historical turning point with the full-scale adoption of artificial intelligence technology. The global biopharmaceutical market size is projected to grow by 8.9%, from $485 billion in 2024 to $528 billion in 2025. Among this, the AI-driven drug development sector is expected to grow by 34.2% year-on-year, reaching a scale of $68 billion. Notably, the drug discovery and development processes utilizing AI and machine learning are becoming the industry standard, moving away from traditional methods. According to a recent report by McKinsey & Company, 95% of the top 20 global pharmaceutical companies are investing in AI-driven drug development platforms, allocating an average of 23% of their R&D budgets to AI-related technologies.
At the heart of this transformation is the fundamental improvement in the efficiency of the drug development process. Traditionally, developing a single new drug took an average of 13-15 years and cost $2.8 billion. However, research indicates that using AI technology can reduce this time to 5-7 years and cut costs by more than half to $1.2-1.5 billion. Particularly, AI algorithms are outperforming human experts in processes such as molecular structure prediction, drug-target interaction analysis, and clinical trial patient selection. Since the release of Google DeepMind’s AlphaFold 3 at the end of 2024, the accuracy of protein structure prediction has reached 96.3%, dramatically improving the drug target discovery process.
Korean biotech companies are also actively investing in and adopting these global trends. Samsung Biologics, headquartered in Songdo, Gyeonggi Province, announced an investment of 350 billion won in the first half of 2025 for an AI-based biopharmaceutical development center, marking the largest single project investment in the company’s history. Similarly, Celltrion in Incheon is automating the antibody drug development process through its proprietary AI platform ‘CelliAI’, reporting a 40% faster discovery of candidate substances as of the fourth quarter of 2024 compared to previous methods. These efforts by Korean companies are linked to the national K-Bio Lagom project, aiming to position Korea among the top five global leaders in the biohealth sector by 2030.
Technological Innovations and Market Dynamics in AI-Driven Drug Development
The most notable technology in the current biotech industry is the molecular design platform utilizing generative AI. Atomwise, headquartered in San Francisco, California, has screened over 12 million compounds through its AtomNet platform by 2025, with 47 of these compounds entering clinical trial stages. This process, which would traditionally take decades, was completed in just a few months, earning the industry label of an ‘industrial revolution in drug development’. Notably, AI has advanced beyond merely analyzing existing compounds to creating entirely new molecular structures.
This technological advancement is accelerating strategic alliances and mergers and acquisitions among global pharmaceutical companies. Roche, headquartered in Basel, Switzerland, invested a total of 1.2 billion Swiss francs in three AI-driven drug development startups in the first quarter of 2025. Johnson & Johnson, headquartered in New Jersey, USA, is expanding its collaboration with AI biotech firms through its innovation division, J&J Innovation. Notably, J&J formed a strategic partnership with the UK-based Exscientia, specializing in AI-driven immuno-oncology drug development, aiming to develop 15 new cancer drug candidates over the next five years.
Market analysts are paying attention to the impact of these changes on the entire value chain of the biotech industry. According to the latest report from Goldman Sachs, the efficiency gains in drug development due to AI adoption are expected to improve the profitability of the global pharmaceutical industry by an average of 18-22% during the 2025-2030 period. This creates a favorable environment particularly for small and medium-sized biotech companies, allowing them to undertake large-scale drug development projects with relatively less capital, which was previously only feasible for large pharmaceutical companies. In fact, venture capital investment in the biotech sector in 2024 increased by 34% year-on-year to $18.7 billion, with 62% focused on companies with AI-based platforms.
However, this rapid technological adoption also presents new challenges. One major concern is the ‘black box’ nature of AI algorithms, leading to delays in regulatory approval. The US FDA released new guidelines for AI-based drugs in early 2025, but there is still a lack of standardized methodologies for evaluating the safety and efficacy of AI-generated compounds. The European Medicines Agency (EMA) has also expressed similar concerns, announcing a review of a separate approval process for AI-based drugs. This regulatory uncertainty could particularly cause delays in the clinical trial phase, with some analysts warning that this could add an additional 12-18 months to the commercialization timeline for AI biotech companies.
Analysis of Global Competition and Investment Trends
The global competitive landscape of the biotech industry in 2025 is characterized by intense technological hegemony competition among the US, Europe, and Asia. The US maintains an absolute advantage, with biotech clusters centered around California and Massachusetts accounting for 47% of global AI-driven drug development investments. Notably, companies such as Genentech (a Roche subsidiary) in the San Francisco Bay Area, Amgen in South San Francisco, and Moderna in Cambridge are making significant investments in building AI platforms. Amgen, for instance, invested $1.5 billion in establishing its own AI research lab in 2024, aiming to discover 20 new therapeutic candidates by 2030.
In the European market, Switzerland and Germany are playing leading roles. Novartis in Basel, Switzerland, is focusing on AI-driven drug repurposing projects through its digital innovation division, completing the discovery of new indications for 2,400 existing approved drugs by the fourth quarter of 2024. In Germany, the biotech startup ecosystem centered around Berlin and Munich is rapidly growing, with the German government’s ‘BioTech 2030’ initiative planning 8 billion euros in public investment over the next five years. BioNTech, headquartered in Munich, is focusing on developing personalized cancer vaccines through the convergence of mRNA technology and AI, with plans to start three clinical trials in the first half of 2025.
In the Asian market, China and Korea are showing rapid progress. In China, biotech companies centered around Beijing and Shanghai are experiencing rapid growth with large-scale support from the government’s ’14th Five-Year Plan’. WuXi AppTec, headquartered in Shanghai, invested 2.5 billion yuan in building an AI-based drug development service platform, actively targeting the outsourcing needs of global pharmaceutical companies. In Korea, besides Samsung Biologics and Celltrion, small and medium-sized bioventures are also showing notable achievements. Aptabio, headquartered in Gangnam-gu, Seoul, discovered an atopic dermatitis drug candidate through its proprietary AI platform and is set to begin Phase 1 clinical trials in the second quarter of 2025.
From an investment perspective, the funding environment in the biotech sector in 2025 has significantly improved compared to the previous year. According to PwC’s analysis, the global biotech IPO market recorded 42 deals worth $8.9 billion in the fourth quarter of 2024, a 67% increase compared to the same period in 2023. Companies with AI-based platforms are receiving valuations on average 2.3 times higher than traditional biotech companies. This increased interest from investors is not only due to expectations of technological excellence but also due to the risk reduction effect from AI adoption. While the success rate of traditional drug development is only 8-12%, the success rate in the early stages using AI-based approaches is reported to improve to 25-30%.
However, alongside these optimistic prospects, there are risk factors that market participants should closely monitor. First, there is the potential for a bubble due to excessive expectations for AI technology. Some analysts warn that the current valuations of AI biotech companies may be overestimated compared to actual performance. Second, there are concerns about data quality and bias. The performance of AI algorithms heavily depends on the quality of training data, and there are worries that a lack of data on rare diseases or specific ethnic groups could affect the efficacy and safety of AI-based drugs. Third, there is the potential for intellectual property disputes. The issue of patent rights for compounds or therapies generated by AI is still without clear legal standards, increasing the likelihood of related litigation in the future.
Despite these challenges, industry experts remain optimistic about the long-term growth potential of the AI-driven biotech industry. According to Deloitte’s latest report, the AI-driven drug development market is expected to reach $280 billion by 2030, representing an annual growth rate of 28.5%. The use of AI technology is expected to significantly increase in personalized medicine and precision healthcare, leading to the development of customized therapies based on individual genetic characteristics and biological information. Furthermore, advancements in AI technology are increasing the likelihood of developing innovative treatments for previously challenging conditions such as Alzheimer’s, Parkinson’s, and various cancers, which is expected to enhance human health and create new market opportunities.
*This analysis is provided for informational purposes only and is not intended as investment advice or a recommendation for trading. Investment decisions should be made based on individual judgment and responsibility.*
